Published in:
01-07-2019 | Oligodendroglioma | Correction
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)
Authors:
Kurt A. Jaeckle, S. K. Anderson, Erin L. Twohy, Jesse G. Dixon, Caterina Giannini, Robert Jenkins, Merrill J. Egorin, Jann N. Sarkaria, Paul D. Brown, P. J. Flynn, John Schwerkoske, Jan C. Buckner, Evanthia Galanis
Published in:
Journal of Neuro-Oncology
|
Issue 3/2019
Login to get access
Excerpt
The last author's first name was truncated in the initial online publication. The original article has been corrected. …